ClinicalTrials.gg
RecruitingNCT06904313Updated Jun 4, 2025

Ultralow Dose PET Imaging for PSMA Expression

A Phase 2 interventional study of Piflufolastat F18 in Healthy Volunteer and Prostate CA, sponsored by Akiva Mintz. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Akiva Mintz · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 9 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.

Planned enrollment
6th of 24
200 · median 55
Started
2025
the only one that year
Phase 2
10 of 24
2 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Akiva Mintz

Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 10 in phase 2, and was the 24th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About piflufolastat

piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing piflufolastat in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:

Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?

Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

Read the detailed description

This research study aims to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. "Investigational" means that the procedure or drug being studied is not yet approved by the FDA for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-DCFPyL, is FDA-approved for detecting prostate cancer at standard doses.

18F-DCFPyL attaches to a protein called PSMA, which is often found at higher levels on certain cancer cells, such as prostate cancer cells. In this study, investigators will use a very small amount of this tracer (less than 1/20th of the standard dose) along with advanced PET imaging technology to see if it is possible to create clear images while using much less radiation. This study aims to develop a safer imaging technique that could potentially be used more frequently for screening and monitoring prostate cancer.

Investigators will enroll individuals with and without prostate cancer to evaluate how ultralow dose PET imaging detects PSMA in different type of tissue.

Approximately 200 people will be enrolled in this study at the Nuclear Imaging Institute.

03

Conditions studied

  • Healthy Volunteer
  • Prostate CA

Browse trials for

Keywords

  • PET scan
  • prostate cancer
  • psma
  • nuclear imaging
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Ability to provide and comply with study procedures.
  3. For female participants:

    • Must not be pregnant or breastfeeding.
    • Negative pregnancy test required for women of .

Exclusion criteria

Exclusion Criteria:

  1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
  2. More than four prior enrollments in this study.
  3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
  4. Medication \& Prior Treatment Exclusions

    • Concurrent PSMA-targeted therapy (e.g., lutetium-177).
  5. Pregnant or breastfeeding individuals (negative pregnancy test required)
  6. Inability to provide
  7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    ultralow dose PSMA imaging group

    Healthy subjects and cancer patients will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours

    Drug: Piflufolastat F18

Interventions

  • DrugPiflufolastatStudies of PiflufolastatPiflufolastat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be injected with Piflufolastat F18 and imaged for up to 3 hours on a PET scanner

    Also known as: CT scan, PET scan, blood collection

06

What researchers measure

Primary outcomes

  1. Signal-to-Noise Ratio (SNR)

    Measurement of signal-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: SNR (unitless, numeric ratio)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  2. Contrast-to-Noise Ratio (CNR)

    Measurement of contrast-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: CNR (unitless, numeric ratio)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  3. Coefficient of Variation (COV)

    Measurement of the coefficient of variation in selected regions for evaluating image consistency across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Percentage (%)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  4. Spatial Resolution (Full Width at Half Maximum - FWHM)

    Assessment of spatial resolution using full width at half maximum (FWHM) across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Millimeters (mm)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  5. Target-to-Background Ratio (TBR)

    Assessment of target-to-background ratio for evaluating PSMA-expressing tissue contrast across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Ratio (unitless numeric ratio)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  6. Qualitative Image Quality Score (Likert Scale)

    Independent qualitative evaluation of overall image quality, lesion detectability, image noise, and artifacts by nuclear medicine physicians, assessed using a 5-point Likert scale. Unit of Measure: Score on Likert Scale (1-5; 1 = worst, 5 = best)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

  7. Inter-reader Agreement (Weighted Kappa Statistics)

    Measurement of agreement among readers evaluating qualitative image quality scores, analyzed using weighted kappa statistics. Unit of Measure: Weighted kappa statistic (numeric value ranging from 0 to 1, 0 = no agreement, 1 = perfect agreement)

    Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2030, 61 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 61 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 1, 2025
StartActual
May 12, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06904313
Lead sponsor
Akiva Mintz
Responsible party
Akiva Mintz (Executive Director, Nuclear Imaging Institute) — Sponsor-investigator
First posted
Apr 1, 2025
Start date
May 12, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jun 4, 2025

Study contacts

Barbara Blanchfield
Contact
bblanchfield@nii.org
9732554955

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piflufolastat

Start the discussion